{"title":"轮状病毒:接种疫苗的证据","authors":"P. Lepage","doi":"10.1097/INF.0b013e31815eedea","DOIUrl":null,"url":null,"abstract":"Rotavirus (RV) is the most common cause of severe acute gastroenteritis in children in developing as well as in industrialized nations. Annually more than 25 million outpatient visits and 2 million hospitalizations are attributable to RV infection in subjects less than 5 years of age. In developing nations about 600000 deaths are caused by RV each year. RV infection is responsible for 21-58% of hospital admission for acute gastroenteritis in Europe. Recently 2 new live orally administered vaccines - Rotarix and RotaTeq - that provide wide protection against RV infections have been developed. These 2 vaccines have recently undergone extensive testing for safety and efficacy. Indeed 2 recent large clinical trials have demonstrated their excellent efficacy and safety including absence of vaccine-associated intussusception in young infants. (excerpt)","PeriodicalId":118937,"journal":{"name":"The Pediatric Infectious Disease Journal","volume":"32 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Rotavirus: Evidence for Vaccination\",\"authors\":\"P. Lepage\",\"doi\":\"10.1097/INF.0b013e31815eedea\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Rotavirus (RV) is the most common cause of severe acute gastroenteritis in children in developing as well as in industrialized nations. Annually more than 25 million outpatient visits and 2 million hospitalizations are attributable to RV infection in subjects less than 5 years of age. In developing nations about 600000 deaths are caused by RV each year. RV infection is responsible for 21-58% of hospital admission for acute gastroenteritis in Europe. Recently 2 new live orally administered vaccines - Rotarix and RotaTeq - that provide wide protection against RV infections have been developed. These 2 vaccines have recently undergone extensive testing for safety and efficacy. Indeed 2 recent large clinical trials have demonstrated their excellent efficacy and safety including absence of vaccine-associated intussusception in young infants. (excerpt)\",\"PeriodicalId\":118937,\"journal\":{\"name\":\"The Pediatric Infectious Disease Journal\",\"volume\":\"32 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Pediatric Infectious Disease Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/INF.0b013e31815eedea\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Pediatric Infectious Disease Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/INF.0b013e31815eedea","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Rotavirus (RV) is the most common cause of severe acute gastroenteritis in children in developing as well as in industrialized nations. Annually more than 25 million outpatient visits and 2 million hospitalizations are attributable to RV infection in subjects less than 5 years of age. In developing nations about 600000 deaths are caused by RV each year. RV infection is responsible for 21-58% of hospital admission for acute gastroenteritis in Europe. Recently 2 new live orally administered vaccines - Rotarix and RotaTeq - that provide wide protection against RV infections have been developed. These 2 vaccines have recently undergone extensive testing for safety and efficacy. Indeed 2 recent large clinical trials have demonstrated their excellent efficacy and safety including absence of vaccine-associated intussusception in young infants. (excerpt)